特应性皮炎患儿在度普利尤单抗获批前后系统性免疫调节剂的纵向使用。
Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
机构信息
Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Pediatr Dermatol. 2023 Jan;40(1):132-134. doi: 10.1111/pde.15172. Epub 2022 Nov 20.
In our cohort study, we sought to describe the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how utilization changed after approval of dupilumab, the first systemic drug approved for the treatment of AD. Using US nationwide claims data, we identified children with AD who initiated a systemic therapy (dupilumab, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil) from March 2015 to February 2021 and used Sankey plots to describe patterns of starting, switching, and discontinuing these drugs. Dupilumab use among children increased from 19.4% before approval in children to 88.3% after approval in 2019-20. Adherence to dupilumab may suggest better tolerance and improved outcomes in children with AD.
在我们的队列研究中，我们旨在描述特应性皮炎 (AD) 儿童中系统性免疫调节剂的使用模式，以及在批准首个用于 AD 治疗的系统性药物度普利尤单抗后，其使用模式如何变化。我们使用美国全国范围内的索赔数据，确定了从 2015 年 3 月至 2021 年 2 月开始接受系统性治疗（度普利尤单抗、环孢素、甲氨蝶呤、硫唑嘌呤和霉酚酸酯）的 AD 儿童，并使用 Sankey 图描述这些药物的起始、转换和停药模式。在 2019-20 年批准后，儿童中度普利尤单抗的使用率从批准前的 19.4%增加到 88.3%。AD 儿童对度普利尤单抗的依从性可能表明其耐受性更好，结局改善。
Zotero 插件